Title |
Poly(ADP-ribose) polymerase inhibition: a new direction for BRCAand triple-negative breast cancer?
|
---|---|
Published in |
Breast Cancer Research, August 2011
|
DOI | 10.1186/bcr2877 |
Pubmed ID | |
Authors |
Ruth Plummer |
Abstract |
Inhibitors of poly(ADP-ribose) polymerase (PARP)-mediated DNA repair have shown promise in early clinical studies in the treatment of specific subgroups of breast cancer. Notably, phase II trials indicate that olaparib, an oral PARP inhibitor, has activity as a single agent in BRCA-related tumours, and that a combination of iniparib, an intravenous PARP inhibitor, and chemotherapy offers a survival advantage, compared with chemotherapy alone, in triple-negative breast cancer. Phase III data on the latter indication are expected in 2011. Intriguingly, iniparib does not increase toxicity when used as a chemo-potentiating agent, suggesting that it differs in its mechanism of action from other agents in this class. Overall, PARP inhibitors represent a potentially important new class of anti-cancer agents with two potential modes of action, as single agents causing synthetic lethality and as chemo-potentiating agents. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Canada | 1 | 1% |
Brazil | 1 | 1% |
Unknown | 85 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 20 | 23% |
Student > Ph. D. Student | 15 | 17% |
Student > Bachelor | 10 | 11% |
Student > Master | 10 | 11% |
Other | 7 | 8% |
Other | 9 | 10% |
Unknown | 16 | 18% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 23 | 26% |
Agricultural and Biological Sciences | 21 | 24% |
Biochemistry, Genetics and Molecular Biology | 16 | 18% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 3% |
Immunology and Microbiology | 2 | 2% |
Other | 5 | 6% |
Unknown | 17 | 20% |